Latest News
Gedea Biotech announce start of the clinical study BV2025 following CE marking of pHyph —first patients enrolled
Gedea Biotech today announced that the clinical trial BV2025 has started, following approval from the Swedish Medical Products Agency…
Gedea Biotech strengthens its Board with extensive commercial expertise to support next phase
Lund, Sweden – November 18, 2025 Gedea Biotech, an innovative Swedish life science company in women’s health, today announced the appointment of…
New insights into the vaginal microbiome: Emilia Lahtinen’s industrial PhD journey
At the intersection of academic research and biotech innovation, Emilia Lahtinen is pursuing her industrial PhD as a collaboration between Gedea…
Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis
Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis
PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm Birth
Gedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s patent application covering the…
About pHyph
pHyph is a CE-marked, antibiotic-free vaginal tablet approved under the EU Medical Device Regulation (MDR) for the treatment of bacterial vaginosis (BV) and for promoting a healthy vaginal microbiome. By restoring the vaginal environment and supporting beneficial lactobacilli, pHyph provides an innovative alternative to conventional treatments. The product is developed by Gedea Biotech to address a significant unmet need for safe and effective treatments that support long-term vaginal health.
About Gedea Biotech
Gedea Biotech AB is a Swedish women’s health company on a mission to make a sustainable impact to global women’s health with a modern, antibiotic-free treatment for common vaginal infections that women can trust for long-term effect, available when they need it. Its lead product pHyph is CE-marked under the EU Medical Device Regulation (MDR) for the treatment of bacterial vaginosis and promotion of a healthy vaginal microbiome. Gedea is a spin out from Lund University and is based in Lund, Sweden.
Supported by the European Innovation Council
The European Innovation Council is Europe’s flagship innovation programme to identify, develop and scale up breakthrough technologies and game changing innovations The EIC has been established under the EU programme. It has a budget of €10.1 billion to support game changing innovations throughout the lifecycle from early stage research, to proof of concept, technology transfer, and the financing and scale up of start-ups and SMEs.
Press Kit
Click to download logos and images.
